secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2023-05-12T23:59:59+00:00
Accession:  0001558370-23-009508
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gain Therapeutics Q1 net loss widens to $5.1M; cash $18.8M supports ops into Q3 2024
--------------------------------------------------------------------------------

- Net loss of $5.1M ($0.43/shr) vs $3.3M ($0.28/shr) YoY; R&D spend rose to $2.8M on pre-IND studies.
- Cash and marketable securities $18.8M at March 31, 2023; ATM proceeds in April extend runway into Q3 2024.
- Completed GLP toxicology for GT-02287 (GBA1 Parkinson's); Phase 1 application to Australian HREC expected mid-2023.
- Secured $2.8M Innosuisse grant for GT-02287 and $1.3M EU consortium grant for AAT program.
- Appointed C. Evan Ballantyne as CFO in April 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000155837023009508/0001558370-23-009508-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000155837023009508/ganx-20230512x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-009508

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer